AC Immune Q3 net loss narrows as revenue rises

AC Immune AG

04/11/2026 12:15

Overview
Switzerland-based neurodegenerative disease biopharma's Q3 revenue rose, driven by Takeda arrangement revenue
Net loss for Q3 narrowed to CHF 8.8 mln from CHF 15.9 mln
Company highlighted positive clinical progress, including FDA Fast Track for ACI-7104

Outlook
Company expects further ACI-7104 clinical data before year-end and ACI-19764 data in early 2027
ACI-7104 antibody characterization data expected before year-end 2026
Initial Phase 1b results for ACI-19764 in cardiovascular patients expected early 2027

Result Drivers
R&D SPEND SHIFT - Lower R&D expenses due to reduced personnel and operational costs, partially offset by higher clinical program spending
TAKEDA ARRANGEMENT - Revenue increase attributed to recognition of additional consideration under Takeda arrangements
FAVORABLE EXCHANGE - Improved financial result driven by more favorable exchange differences

Company press release: ID:nGNE9DzwPb

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Loss Per Share
 
CHF 0.13
 
Q3 Net Loss
 
CHF 8.75 mln
 
Q3 Operating Expenses
 
-CHF 13.05 mln
 
Q3 Operating Income
 
-CHF 9.80 mln
 
Q3 Pretax Loss
 
CHF 8.75 mln
 

Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy."
Wall Street's median 12-month price target for AC Immune AG is $9.47, about 353.1% above its November 3 closing price of $2.09

Reuters Recommended Reads
Nov 4 - Swiss pharma industry behind in technology and clinical trials, index shows
Nov 2 - Switzerland's CRISPR Therapeutics Q3 CASGEVY revenue jumps 30% sequentially
Nov 3 - Ultragenyx Q3 revenue rises, net loss narrows

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)